| Samuel Benjamin Huxley, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Samuel Benjamin Huxley |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 6 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023511870 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 68679 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic | 6507778255 | 4232 |
News Archive
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows.
Student athletes will soon have access to free injury evaluations by an orthopaedic physician on Saturdays at the Andrews Institute for Orthopaedics & Sports Medicine.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with BioPro Pharmaceutical, Inc. ("BioPro"), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the "Territories").
Aggressive treatment for severe traumatic brain injuries costs more than routine care, yet yields significantly better outcomes, improved quality of life, and lower long term care costs, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania.
Birner Dental Management Services, Inc., operators of PERFECT TEETH® dental practices, announced results for the year and quarter ended December 31, 2009. For the year ended December 31, 2009, revenue increased $557,000, or 0.9%, to $59.6 million. The Company's earnings before interest, taxes, depreciation, amortization and non-cash expense associated with stock-based compensation ("Adjusted EBITDA") increased $101,000, or 1.5%, to $6.9 million.
› Verified 8 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows.
Student athletes will soon have access to free injury evaluations by an orthopaedic physician on Saturdays at the Andrews Institute for Orthopaedics & Sports Medicine.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with BioPro Pharmaceutical, Inc. ("BioPro"), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the "Territories").
Aggressive treatment for severe traumatic brain injuries costs more than routine care, yet yields significantly better outcomes, improved quality of life, and lower long term care costs, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania.
Birner Dental Management Services, Inc., operators of PERFECT TEETH® dental practices, announced results for the year and quarter ended December 31, 2009. For the year ended December 31, 2009, revenue increased $557,000, or 0.9%, to $59.6 million. The Company's earnings before interest, taxes, depreciation, amortization and non-cash expense associated with stock-based compensation ("Adjusted EBITDA") increased $101,000, or 1.5%, to $6.9 million.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samuel Benjamin Huxley, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Samuel Benjamin Huxley, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows.
Student athletes will soon have access to free injury evaluations by an orthopaedic physician on Saturdays at the Andrews Institute for Orthopaedics & Sports Medicine.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with BioPro Pharmaceutical, Inc. ("BioPro"), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the "Territories").
Aggressive treatment for severe traumatic brain injuries costs more than routine care, yet yields significantly better outcomes, improved quality of life, and lower long term care costs, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania.
Birner Dental Management Services, Inc., operators of PERFECT TEETH® dental practices, announced results for the year and quarter ended December 31, 2009. For the year ended December 31, 2009, revenue increased $557,000, or 0.9%, to $59.6 million. The Company's earnings before interest, taxes, depreciation, amortization and non-cash expense associated with stock-based compensation ("Adjusted EBITDA") increased $101,000, or 1.5%, to $6.9 million.
› Verified 8 days ago
Emily Leasure, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jorge A Velosa, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michael Ruediger Mueller, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mr. Karun Singh Badwal, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michal Reid, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Katherine Desprez Wick, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Allison Bock, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |